Meet Phat Le, M.D.
Phat Le, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology (Joint Appointment), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Oncology Lead (HALs Sugar Land), Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | UT Southwestern Medical School, Dallas, Texas, US, MD |
| 2005 | University of Texas at Austin, Austin, Texas, US, Microbiology, BS |
Postgraduate Training
| 2024-2025 | Clinical Safety and Effectiveness, Clinical Safety and Effectiveness, MD Anderson Cancer Center, Houston, Texas |
| 2020-2020 | Epic Certification, Epic Power User, MD Anderson Cancer Center, HOUSTON, Texas |
| 2020-2021 | Leading Others Accelerate Program, Leadership, MD Anderson Cancer Center, HOUSTON, Texas |
| 2020-2020 | Clinical Safety and Effectiveness, Clinical Safety and Effectiveness, MD Anderson Cancer Center, HOUSTON, Texas |
| 2012-2015 | Clinical Fellowship, Hematology/Oncology, UT Southwestern Medical Center, Dallas, Texas |
| 2009-2012 | Clinical Residency, UT Southwestern Medical Center, Dallas, Texas |
Licenses & Certifications
| 2024 | Washington State Department of Health |
| 2024 | DEA |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Florida Board of Medicine |
| 2023 | Georgia Composite Medical Board |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2022 | Alabama Board of Medical Examiners |
| 2012 | Texas Medical Board |
| 2012 | American Board of Internal Medicine - Medical Oncology |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Clinical Assistant Professor, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, 2017 - 2018
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Assistant Professor, Department of General Oncology, Houston Methodist Institute for Academic Medicine/Weill Cornell Medical College, Houston, TX, 2016 - 2017
Assistant Professor, Houston Methodist Specialty Physicians Group, Houston, TX, 2015 - 2017
Administrative Appointments/Responsibilities
Beacon Oncology User Group Committee Member, Parkland Health and Hospital System, Dallas, TX, 2014 - 2015
Chief Hematology/Oncology Fellow, University of Texas Southwestern, Dallas, TX, 2014 - 2015
Parkland Oncology Clinic Staff Committee Member, Parkland Health and Hospital System, Dallas, TX, 2014 - 2015
Intramural Institutional Committee Activities
Member, Histotripsy Oversight Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Quality Goal SuperUser, OP-35 Service Line Steering Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Extramural Institutional Committee Activities
GI Service Line Co-Lead, OP-35 Service Line Steering Task Force, MD Anderson Cancer Center, 2024 - Present
Member, Rapid Turn Around Time Liquid Biopsy Working Group, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Chair, Colorectal Multidisciplinary Working Group, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, GI Service Line Workgroup Local Provider Referral Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Flush Therapy Plan Project Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Houston Area Location Integration Work Group Co-Lead, GI Service Line Workgroup, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, GI Medical Oncology Burnout Task Force, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Houston Area Locations Research Expansion Operations Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, Faculty Senate Houston Area Locations Working Group, The University of Texas MD Anderson Cancer Center, 2020 - 2020
Member, Ambulatory Informatics Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, ad interim, HALS Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Department Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2019 - 2021
Officer, Department EHR Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, EHR Provider Experience Subcommittee, The University of Texas MD Anderson Cancer Center, 2018 - 2019
Medical Oncology Representative, HALS Clinical Research Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Member, Houston Methodist Cancer Center EPIC Validation Committee, Houston Methodist Hospital, 2015 - 2017
Member, Cancer Committee, Houston Methodist West Houston, 2015 - 2017
Honors & Awards
| 2024 | Zero Heroes-Providers who had 1000+ encounters closed on average in less than 1 day, MD Anderson Cancer Center |
| 2021 - 2022 | Zero Heroes-Providers who had 1000+ encounters closed on average in less than 1 day, MD Anderson Cancer Center |
| 2020 | Top 10% Provider, Clinician and Group Consumer Assessment of Healthcare Providers and Systems |
| 2019 | Top Houston Area Location Provider for Research Referrals, MD Anderson Cancer Center |
| 2019 | You Make the Difference-Fastest to Close Encounters, MD Anderson Cancer Center, Division of Cancer Medicine 14th Annual Faculty Recognition and Awards Program |
| 2019 | Top HALS Provider for Research Referrals, MD Anderson Cancer Center |
| 2018 | Top 1% Provider, Clinician and Group Consumer Assessment of Healthcare Providers and Systems |
| 2014 - 2015 | UT Southwestern Hematology/Oncology Chief Fellow |
| 2014 | Hematology/Oncology Academic Achievement awarded to the fellow with the highest score on the annual ASCO in-service exam, UT Southwestern |
| 2011 | Parkland Hospital Employee of the Month |
| 2005 - 2006 | Southwestern Medical Foundation Scholarship for Academic Achievement |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Evidence-based Second/Third-line Treatment and Beyond. Invited. Bayer Colorectal Education Session. Houston, Texas, US.
Selected Publications
Peer-Reviewed Articles
- Morris VK, Parseghian CM, Bahrambeigi V, Abdelfattah N, Xiao L, Agrawal A, Lin K, Raghav KPS, Wolff RA, Dasari A, Huey RW, Kee BK, Overman MJ, Willis JA, Le PH, Escano M, Baig YC, Pan K, Menter D, Tam AL, Foo WC, Shen L, Lee HM, Gallup TD, Margain C, Gallup D, Rajapakshe KI, Guerrero PA, Wang J, Corcoran RB, Maitra A, Yun K, Kopetz S. Phase 1/2 Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAF(V600E) Metastatic Colorectal Cancer. Cancer Cell, 2025. e-Pub 2025. PMID: 40882637.
- Pellatt AJ, Bent A, Hornstein N, Parseghian C, Huey R, Raghav K, Morris V, Overman M, Morelli P, Willis J, Le P, Shen JP, Kee B, Eluri M, Higbie V, Alfaro-Munoz K, Aziz K, Kell R, Sun R, Kopetz S, Dasari A. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT. JCO Precis Oncol, 2025. e-Pub 2025. PMID: 40669021.
- Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Regorafenib in Patients with Solid Tumors with BRAF Alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol 8:e2300527, 2024. e-Pub 2024. PMID: 38603652.
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
- Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y. Predictors and Impact of Second-line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-world considerations for maintenance therapy. J Thorac Oncol 6(2):365-71, 2011. e-Pub 2011. PMID: 21173713.
Abstracts
- Huey RW, Zafar A, Le P, Sanchez NE, Patlovich K, Olivieri ND, Overman MJ, Rivera JA, Roux R, Adelson KB. Performance characteristics of CMS' OP-35 quality measure: Sensitive but not specific, 2025. e-Pub 2025.
- Allam J, Estrella J, Higbie V, Le P, Bent A, Kotlov N, Baranov O, Tongsai F, Paradiso F, Samarina N, Galanicheva N, Hensley M, Fowler N, Willett A, Nguyen V, Matamoros A, Lano E, Raghav K, Huey R. Uncovering the tumor microenvironment (TME): Exploring survival and immunotherapy (IO) response in cancer of unknown primary (CUP). 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
- Huey RW, Zafar A, Le P, Sanchez NE, Patlovich K, Olivieri ND, Singhi EK, Rivera JA, Roux R, Adelson KB. OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively?. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
- Shah AT, Estrella J, Dasari P, Willett A, Allam J, Higbie V, Le P, Lee MS, Matamoros A, Lano EA, Raghav KPS, Huey RW. Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset. J Clin Oncol 41(16):3606, 2023. e-Pub 2023.
- Simmons K, Kee BK, Raghav KPS, Johnson B, Kopetz S, Willis J, Dasari A, Sanchez EV, Ludford K, Parseghian M, Lee MS, Le P, Shen JP, Overman MJ, Morris VK. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol 40(16):3585, 2022. e-Pub 2022.
- Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KPS, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Le P, Margain C, Gallup D, Tam A, Foo WC, Xiao L, Yun K, Kopetz S. Phase I/II trial of enorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAF V600E metastatic colorectal cancer. J Clin Oncol 40(16):3598, 2022. e-Pub 2022.
- Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Raghav KPS, Kee BK, Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. J Clin Oncol 40(16):3592, 2022. e-Pub 2022.
- Bhamidipati D, Raghav KPS, Morris VK, Kopetz S, Kee BK, Johnson B, Willis J, Dasari A, Morelli MP, Parseghian CM, Lee MS, Le P, Shen JP, Ludford K, Overman M. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol 40(16):3524, 2022. e-Pub 2022.
- Wiele AJ, Nguyen T, Ononogbu A, Russo KM, Le P, Patel TA, Ma HY, Rieber AG. Reducing the wait time to initiate inpatient chemotherapy at Lyndon B. Johnson Hospital. J Clini Oncol; ASCO Quality Care Symposium, Poster Highlights Session, October 2020 38(29), 2020. e-Pub 2020.
- Le P, Law JY, Dao BD, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Treatment of Adolescent Young Adults with Acute Lymphoblastic Leukemia: 10-year outcome data from single institution 33(15), 2015. e-Pub 2015.
- Dao BD, Law JY, Le P, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Clinical Outcome of Adult Acute Lymphoblastic Leukemia based on Philadelphia Chromosome Status and Socioeconomic Status 33(15), 2015. e-Pub 2015.
- Law JY, Dao BD, Le P, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Impact of body mass index and ethnicity on asparaginase toxicity in adult acute lymphoblastic leukemia patients. J Clin Oncol 2015; American Society of Clinical Oncology (ASCO), May 2015, Chicago, IL 33(15), 2015. e-Pub 2015.
Book Chapters
- Ramzan Z, Le P, Kapur P, Huerta S. Current Concepts in Pancreatic Cancer. In: Updates on Cancer Treatment, Prof. Leticia Rangel (Ed.). In TECH, 2015.
Patient Reviews
CV information above last modified October 15, 2025